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Glycopeptides and β-lactams are the 
major antibiotics available for the treatment 
of infections due to Gram-positive bacteria. 
Emergence of cross-resistance to these drugs 
by a single mechanism has been considered as 
unlikely since they inhibit peptidoglycan 
polymerization by different mechanisms. The 
glycopeptides bind to the peptidyl-D-Ala4-D-
Ala5 extremity of peptidoglycan precursors 
and block by steric hindrance the essential 
glycosyltransferase and D,D-transpeptidase 
activities of the penicillin-binding proteins 
(PBPs). The β-lactams are structural 
analogues of D-Ala4-D-Ala5 and act as suicide 
substrates of the D,D-transpeptidase module of 
the PBPs. Here we show that bypass of the 
PBPs by the recently described β-lactam-
insensitive L,D-transpeptidase from 
Enterococcus faecium (Ldtfm) can lead to high-
level resistance to glycopeptides and β-
lactams. Cross-resistance was selected by 
glycopeptides alone or serially by β-lactams 
and glycopeptides. In the corresponding 
mutants, UDP-MurNAc-pentapeptide was 
extensively converted to UDP-MurNAc-
tetrapeptide following hydrolysis of D-Ala5, 
thereby providing the substrate of Ldtfm. 
Complete elimination of D-Ala5, a residue 
essential for glycopeptide binding, was 
possible since Ldtfm uses the energy of the L-
Lys3-D-Ala4 peptide bond for cross-link 
formation in contrast to PBPs which use the 
energy of the D-Ala4-D-Ala5 bond. This novel 
mechanism of glycopeptide resistance was 
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unrelated to the previously identified 
replacement of D-Ala5 by D-Ser or D-lactate. 
 
Therapeutic usage of antibiotics has 
invariably led to emergence of resistance in 
target pathogens and members of commensal 
flora submitted to the same selective pressure. 
This scenario differs greatly between antibiotics 
with respect to the time period separating initial 
drug marketing and emergence of resistance (1). 
Detoxification of penicillin was recognized 
before the first therapeutic usage of the drug (2) 
and acquisition of resistance has immediately 
been a medical concern (3). In contrast, acquired 
resistance to glycopeptides was detected for the 
first time in enterococci 28 years after 
vancomycin had been launched in 1956 (4). 
During this unusually long delay, glycopeptides 
were considered as “irresistible” antibiotics and 
it has been rationalized that this class of drugs 
remained unharmed because of its unique mode 
of action (5). The drugs bind to the peptidyl-D-
Ala4-D-Ala5 extremity of peptidoglycan 
precursors at the bacterial cell surface and block 
the transglycosylation and transpeptidation 
reactions by steric hindrance (Fig. 1A). This 
mode of action implies that acquisition of 
resistance cannot be easily achieved because 
modification of the target is limited by the 
specificity of multiple biosynthetic enzymes (5) 
including the Ddl ligase for synthesis of D-Ala-
D-Ala, the MurF ligase for addition of the 
resulting dipeptide to the nascent cytoplasmic 
precursor, and the D,D-transpeptidases for 
peptidoglycan cross-linking in the last step of 
peptidoglycan polymerization (6). The latter 
reaction is catalyzed by penicillin-binding 
proteins (PBPs) that cleave the D-Ala4-D-Ala5 
bond of a donor stem pentapeptide and link the 
carboxyl of D-Ala4 to the amino group of the 
side chain carried by the third residue of an 
acceptor stem peptide (Fig. 1A). 
Glycopeptide resistance has emerged in the 
enterococci (4) by acquisition of transposon 
Tn1546 which mediates production of precursors 
terminating in D-lactate (D-Lac) instead of D-Ala 
(7, 8). The substitution leads to a 1,000-fold 
reduction in the affinity of vancomycin for its 
target (9). Tn1546 encodes two biosynthetic 
enzymes for reduction of pyruvate into D-Lac 
(VanH) and synthesis of the depsipeptide D-Ala-
D-Lac (VanA) (8). In addition, elimination of 
precursors ending in D-Ala is required for 
resistance. This function is carried out by two 
Tn1546-encoded D,D-peptidases which 
hydrolyzes D-Ala-D-Ala (VanX) and 
cytoplasmic precursors containing a stem 
pentapeptide (VanY) (10). Dissemination of 
Tn1546 and related elements specifying the 
production of precursors ending in D-Ala-D-Lac 
is currently responsible for the high incidence of 
glycopeptide resistance in the enterococci and its 
emergence in methicillin-resistant 
Staphylococcus aureus (11, 12). In addition, 
low-level resistance to vancomycin can result 
from production of precursors ending in D-Ser 
(13, 14). Finally, substitution of D-Ala by D-2-
hydroxybutyrate and D-2-hydroxyvalerate has 
been obtained in mutants constructed in vitro 
(15). 
In this report, in vitro selection of high-level 
resistance to glycopeptides in E. faecium has 
been reevaluated in the light of our recent 
characterization of an L,D-transpeptidase (Ldtfm) 
that specifically cross-links stem tetrapeptide 
lacking D-Ala5 in a β-lactam insensitive reaction 
(Fig. 1B) (16). Since D-Ala5 is essential for 
glycopeptide binding (17), peptidoglycan cross-
linking by Ldtfm cannot be inhibited by these 
drugs. Here, we show that activation of the L,D-
transpeptidation pathway can also release 
inhibition of transglycosylation leading to cross-
resistance to glycopeptides and β-lactams 
following extensive hydrolysis of D-Ala5 from 
the cytoplasmic precursor UDP-MurNAc-
pentapeptide by a D,D-carboxypeptidase. 
Characterization of this novel mechanism of 
glycopeptide resistance establishes for the first 
time that the fifth C-terminal residue of the stem 
peptide is dispensable for peptidoglycan 
polymerization.  
 
EXPERIMENTAL PROCEDURES 
 
Bacterial Strains, Growth Conditions, and 
Selection of Mutants Resistant to Glycopeptides 
– All cultures were performed at 37 °C in brain 
heart infusion (BHI) agar or broth (Difco 
Laboratories, Detroit, MI). A standard procedure 
was used for selection of mutants resistant to 
glycopeptides (18). Briefly, an inoculum of 4 X 
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109 colony forming units was prepared in broth 
and plated on agar containing 2-fold increasing 
concentrations of antibiotics. Selection steps that 
gave negative results were repeated with 1.3-fold 
increasing drug concentrations (selection of 
mutants G3 and G4). Mutants appeared after 3 to 
5 days of incubation with a frequency of about 
10-9 (1 to 15 colonies per plate). The selection 
procedure was repeated at each step with a 
mutant growing in the presence of the highest 
drug concentration. Spontaneous mutants G1 to 
G9 were obtained from E. faecium D344S (18) 
by using nine serial selection steps on agar 
containing increasing concentrations of 
glycopeptides. The concentrations of 
vancomycin were 4, 6, 8, 12, 16, 32, and 64 
µg/ml for mutants G1, G2, G3, G4, G5, G6, and 
G7, respectively. Mutants G8 and G9 were 
selected with teicoplanin at 2 and 64 µg/ml, 
respectively. Mutants M6 to M9 were obtained 
from E. faecium M512 (18) by four serial 
selection steps on agar containing vancomycin at 
16 (M6), 64 (M7), and 1,000 (M8) µg/ml or 
teicoplanin at 128 µg/ml (M9). Minimal 
inhibitory concentrations of ampicillin (Bristol-
Myers, Paris, France), vancomycin (Merck, 
Lyon, France), and teicoplanin (Aventis, Paris, 
France) were determined by the agar dilution 
method after 48 h of incubation (18).  
Preparation and Analysis of Cytoplasmic 
Peptidoglycan Precursors – Bacteria were 
grown to an optical density at 650 nm of 0.35 in 
400 ml of BHI broth and treated with bacitracin 
(200 µg/ml) for 5 min. Ice-cold formic acid (47 
ml, 1.1 M) was rapidly added to the bacterial 
pellet and nucleotide precursors were extracted 
for 30 min at 4°C. The extract was centrifuged 
(7,000 X g for 15 min at 4°C), the pH of the 
supernatant was adjusted to 6.0 with ammonium 
hydroxide, and lyophilized. Peptidoglycan 
precursors were analyzed by rp-HPLC with a 
C18 column (hypersil 4.6 by 250 mm, Interchim, 
Montluçon, France) at a flow rate of 0.5 ml/min 
with 50 mM ammonium formiate (pH 4.0). A 
methanol gradient (0-20%) was applied between 
29 and 47 min and elution was continued for 20 
min with 20% methanol. The relative abundance 
of the UDP-MurNAc-peptides was estimated by 
the percent of the integrate area of peaks 
detected by the absorbance at 262 nm. Products 
isolated by rp-HPLC were analyzed by mass 
spectrometry (MS) using an electrospray time-
of-flight mass spectrometer operating in positive 
mode (Qstar Pulsar I, Applied Biosystem, 
Courtaboeuf, France) (19). Tandem mass 
spectrometry (MS-MS) was performed with 
nitrogen as the collision gas (19).  
D,D-Carboxypeptidase Activity – Preparation of 
membrane extracts by sonication and 
determination of D-Ala release from L-Ala-D-γ-
Glu-L-Lys-D-Ala-D-Ala (Sigma-Aldrich, St. 
Louis, Mo) using D-amino oxydase coupled to 
peroxidase was performed as previously 
described (10). Ampicillin (20 µg/ml) was used 
to inhibit the D,D-carboxypeptidase activity of 
penicillin-binding proteins (18). D,D-
carboxypeptidase activity was expressed as 
nmole of D-Ala produced per min and per mg of 
protein in the extract.  
Peptidoglycan Structure Analysis – Bacteria 
were grown at 37°C to an optical density of 0.35 
at 650 nm in 500 ml of BHI broth. Peptidoglycan 
was extracted with boiling SDS, treated with 
proteases, and digested with mutanolysin and 
lysozyme, as previously described (20). The 
resulting muropeptides were treated with 
ammonium hydroxide to cleave the ether link 
internal to MurNAc, separated by rp-HPLC, and 
analyzed by MS and MS/MS (20).  
Western Blot Analysis – Anti Ldtfm antiserum 
was obtained by three subcutaneous injections at 
2 weeks intervals of 500 µg of purified protein 
(residues 119-466, ref. 16) in a New-Zealand 
rabbit. Bacteria were lysed in phosphate buffer 
(50 mM pH 7.0) with 0.17 µM glass beads (3 X 
30s, FastPrep, Q-biogen, Illkirch, France). 
Proteins were separated by SDS-PAGE, 
electrotransferred to a nitrocellulose membrane 
(Hybond, Amerham, Biosciences, Little 
Chalfont, UK), and incubated with the anti Ldtfm 
antiserum at a 1/1000 dilution. Goat anti rabbit 
IgG coupled to peroxidase (SouthernBiotech, 
Birmingham, AL) was used as secondary 
antibodies and Ldtfm was detected by 
chemiluminescence (ECL kit, Pierce, Amersham 
Biosciences).  
 
RESULTS 
 
Sequential Acquisition of Ampicillin and 
Glycopeptide Resistance – We have previously 
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reported activation of the L,D-transpeptidation 
pathway (Fig. 1B) under the selective pressure of 
β-lactams (18, 21). Selection led to mutant M512 
which is highly resistant to ampicillin whereas 
resistance to glycopeptides was not tested. As 
shown in Fig 2A, acquisition of high-level 
resistance to ampicillin in M512 (MIC >2,000 
µg/ml) led only to a marginal increase (2-fold) in 
the MICs of vancomycin and teicoplanin. Thus, 
activation of the L,D-transpeptidation pathway 
was not sufficient in itself for glycopeptide 
resistance. Four additional steps of selection with 
glycopeptides were required to obtain mutant 
M9 that was cross-resistant to high levels of 
ampicillin and glycopeptides (Fig. 2A). 
Acquisition of High-Level Cross-Resistance to 
Glycopeptides and Ampicillin under the Selective 
Pressure of Glycopeptides – E. faecium D344S 
was used to monitor the emergence of 
ampicillin-resistance under glycopeptide 
selection since this strain is highly susceptible to 
ampicillin due to the spontaneous deletion of the 
pbp5 gene encoding a low-affinity penicillin-
binding protein (PBP5) (18). Mutant G9 was 
obtained from D344S by nine serial selection 
steps on agar containing increasing 
concentrations of glycopeptides (Fig. 2B). The 
selection procedure led to 250- and 1,000-fold 
increases in the minimal inhibitory 
concentrations (MICs) of vancomycin (from 4 to 
1,000 µg/ml) and teicoplanin (from 0.25 to 250 
µg/ml). Even though ampicillin was not used, 
the selection procedure led also to the acquisition 
of high-level resistance to this antibiotic with a 
>36,000-fold increase in its MIC (from 0.06 to 
>2,000 µg/ml). This is the first report of 
emergence of cross-resistance to β-lactams under 
the selective pressure of glycopeptides. 
UDP-MurNAc-Tetrapeptide is the Main 
Cytoplasmic Peptidoglycan Precursors of 
Mutant M9 and G9 – To gain insight into the 
mechanism of resistance, the structure of 
cytoplasmic peptidoglycan precursors was 
determined by mass spectrometry (Fig. 3 and 
Table 1). The parental strain D344S produced 
mainly UDP-MurNAc-pentapeptide (93 %) and 
small amounts of UDP-MurNAc-tetrapeptide 
(7%). Activation of the L,D-transpeptidation 
pathway in mutant M512 led to an increase in 
the pool of UDP-MurNAc-tetrapeptide from 7 to 
60 %. The proportion of UDP-MurNAc-
tetrapeptide was further increased in mutants M9 
(>99 %) and G9 (92%). Thus, co-production of 
UDP-MurNAc-pentapeptide and UDP-MurNAc-
tetrapeptide was associated with resistance to 
ampicillin only whereas extensive elimination of 
UDP-MurNAc-pentapeptide was associated with 
cross-resistance to ampicillin and glycopeptides. 
Strikingly, UDP-MurNAc-pentapeptide was 
undetectable in M9 indicating that the wild-type 
precursor is dispensable for peptidoglycan 
synthesis in this mutant.  
Activation of a Cryptic D,D-Carboxypeptidase is 
Responsible for Accumulation of UDP-MurNAc-
Tetrapeptide – Membrane extracts of the 
parental strain D344S contained low D,D-
carboxypeptidase activity (Table 1). Inhibition 
by ampicillin indicated that hydrolysis of 
pentapeptide was mediated by the D,D-peptidase 
activity of PBPs (18). In contrast, mutants M512, 
M9, and G9 produced an additional D,D-
carboxypeptidase that was insensitive to 
inhibition by ampicillin (Table 1). Thus, 
accumulation of UDP-MurNAc-tetrapeptide in 
the cytoplasm was due to hydrolysis of the UDP-
MurNAc-pentapeptide by a D,D-
carboxypeptidase that was not produced by the 
parental strain D344S. Surprisingly, the D,D-
carboxypeptidase activity was not increased in 
mutant M9 in comparison to M512 in spite of an 
increase in the pool of UDP-MurNAc-
tetrapeptide (from 60 to >99 %).  
The Mutants M512, M9, and G9 Produce Wild-
Type Enzymes for the Assembly of UDP-
MurNAc-pentapeptide – The enzymes for 
incorporation of D-Ala at positions 4 and 5 of the 
nucleotide precursors (Fig. 1A) (6) were further 
investigated to eliminate the possibility that 
resistance to glycopeptides involved 
translocation of precursors carrying substitutions 
at the C-terminal positions of stem peptides. We 
also examined by the same approach the 
possibility that accumulation of UDP-MurNAc-
tetrapeptide in the cytoplasm could result from 
production of modified precursors that would be 
more sensitive to hydrolysis than wild-type 
precursors.  
DNA sequencing revealed that mutants 
M512, M9, and G9 harbor wild-type Ddl and 
MurF ligases for synthesis of the dipeptide D-
Ala-D-Ala and its addition onto UDP-MurNAc-
tripeptide, respectively (Fig. 1). Likewise, no 
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mutation was detected in the aslfm gene encoding 
the ligase for addition of the side chain D-
aspartate residue to peptidoglycan precursors 
(22).  
To confirm the in vivo specificity of these 
enzymes, the precursor pools of the mutants 
were thoroughly investigated to look for 
alternate precursors (data not shown). UDP-
MurNAc-tripeptide was not detected indicating 
that the D-Ala-D-Ala substrate of the MurF ligase 
was not limiting, as previously found in 
glycopeptide-dependant enterococci (23). 
Precursors containing a side chain D-iso-aspartyl 
or D-iso-asparaginyl residue (D-iAsx) were 
present in both strains. Thus, the pathway for 
incorporation of D-Asp into the precursors and 
the subsequent amidation of its α-carboxyl group 
was not altered in the mutants.  
Precursors containing D-Lac or D-Ser at the 
fifth position of stem peptides were not detected. 
Since the procedures used for the extraction of 
the precursors did not lead to the hydrolysis of 
D-alanyl-D-lactate ester bounds (data not shown), 
these results indicate that glycopeptide resistance 
in mutants M9 and G9 does not involve 
replacement of the C-terminal D-Ala residues of 
nucleotide precursors. 
Total By-Pass of PBPs by Ldtfm in Mutant M9 – 
The peptidoglycan of mutant M9 was analyzed 
by mass spectrometry to evaluate the 
contribution of the D,D-transpeptidase activity of 
PBPs and of the L,D-transpeptidase activity of 
Ldtfm to the formation of cross-links (Fig. 4). 
Sequencing of dimers by tandem mass-
spectrometry (Fig. 5) indicated that the 
peptidoglycan manufactured by M9 during 
growth in the absence of antibiotic exclusively 
contained L-Lys3→D-iAsx-L-Lys3 cross-links 
generated by L,D-transpeptidation. This indicates 
that the donor substrate of the D,D-
transpeptidases, which contains a stem 
pentapeptide, was not present in mutant M9 in 
agreement with the analysis of cytoplasmic 
peptidoglycan precursors (Table 1). In contrast, 
cross-links were both generated by L,D-
transpeptidation and D,D-transpeptidation in 
mutant M512 grown in the absence of antibiotic 
(data not shown and ref. 18).  
Analysis of the muropeptide composition 
was repeated for cultures of M9 performed in the 
presence of ampicillin (64 µg/ml), teicoplanin 
(32 µg/ml), or both antibiotics. The rp-HPLC 
profiles were very similar and mass spectrometry 
analysis did not reveal any modification of the 
structure of the lactoyl-peptides (data not 
shown). These observations confirm that 
glycopeptides and β-lactams had no effect on 
peptidoglycan synthesis in mutant M9. 
A minority of the muropeptides of mutants 
M9 was found to contain Gly instead of D-Ala at 
the 4th position of stem peptides (Fig. 4). As 
glycine-containing precursors have not been 
detected in the cytoplasm, it is likely that 
incorporation of this residue results from 
exchange of D-Ala by Gly, a reaction previously 
shown to be catalyzed by Ldtfm in vitro (16). In 
conclusion, substitution of D-Ala4→D-iAsx-L-
Lys3 by L-Lys3→D-iAsx-L-Lys3 cross-links and 
partial replacement of D-Ala4 by Gly4 were the 
only differences detected in the peptidoglycan of 
M9 in comparison to the peptidoglycan of wild-
type strains of E. faecium.  
Activation of the L,D-Transpeptidation Pathway 
in Response to The Selective Pressure of 
Glycopeptides in Mutant G9 – The muropeptide 
monomers from mutant G9 and the parental 
strain D344S were similar confirming that 
atypical precursors are not produced by mutant 
G9 (data not shown). The substantial majority 
(97 %) of the dimers from the susceptible strain 
D344S contained the usual D-Ala4→D-iAsx-L-
Lys3 cross-links generated by the β-lactam-
sensitive D,D-transpeptidase activity of the PBPs. 
The remaining dimers (3%) were produced by 
L,D-transpeptidation as they contained L-
Lys3→D-iAsx-L-Lys3 cross-links. In contrast, the 
muropeptide oligomers of mutant G9 mainly 
contained these L-Lys3→D-iAsx-L-Lys3 cross-
links. Tandem mass spectrometry indicated that 
modification of the cross-links and substitution 
of D-Ala4 by Gly4 were the only differences in 
the structure of the peptidoglycan from D344S 
and G9 (data not shown). Thus, the selective 
pressure of glycopeptides led to the activation of 
the L,D-transpeptidation pathway previously 
identified in ampicillin-resistant mutants of E. 
faecium (21). In contrast to M9, cross-links 
generated by D,D-transpeptidation were detected 
in a minority of the dimers of mutant G9. This 
difference correlates with the complete (< 1%) or 
partial (8 %) elimination of UDP-MurNAc-
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pentapeptide from the cytoplasm of M9 and G9, 
respectively (Table 1). 
 
DISCUSSION 
β-lactams and glycopeptides are frequently 
the only alternative options for the treatment of 
severe infections due to Gram-positive bacteria. 
Acquired resistance to these antibiotics mainly 
results from two independent mechanisms 
involving production of low-affinity PBPs (24) 
and incorporation of D-Lac or D-Ser instead of 
D-Ala at the C-terminal position of 
peptidoglycan precursors (8). Neither of the two 
mechanisms confers alone cross-resistance and 
synergistic effects have been reported in certain 
strains of E. faecium in which inducible 
production of precursors ending in D-Lac 
increases susceptibility to β-lactams presumably 
because substitution of D-Ala by D-Lac impairs 
peptidoglycan cross-linking by low-affinity 
PBP5 (25). In this report, bypass of the PBPs by 
the Ldtfm L,D-transpeptidase was investigated as 
a potential mechanism of cross-resistance, since 
the tetrapeptide substrate of Ldtfm is not 
recognized by glycopeptides and since this 
enzyme is not inhibited by β-lactams. We show 
that cross-resistance can be selected by 
ampicillin and glycopeptides sequentially or by 
glycopeptides alone. The two selection schemes 
led to activation of the L,D-transpeptidation 
pathway which allowed extensive elimination of 
precursors containing the target of 
glycopeptides. 
The first selection scheme revealed that 
high-level resistance to β-lactams and cross-
resistance to glycopeptides can emerge 
sequentially under the selective pressure of 
ampicillin and glycopeptides. We have 
previously shown that selection by ampicillin 
leads to activation of the L,D-transpeptidation 
pathway (18, 21), but the resulting mutant, 
M512, remained susceptible to glycopeptides 
(Fig. 2A) and four additional selection steps with 
glycopeptides were required for cross-resistance 
(mutant M9). Hydrolysis of the C-terminal D-
Ala5 residue of cytoplasmic precursors was 
complete in M9 (<1% UDP-MurNAc-
pentapeptide) whereas a significant proportion of 
the precursors of M512 contained the peptidyl-D-
Ala4-D-Ala5 target of glycopeptides (40% UDP-
MurNAc-pentapeptide). Thus, M512 produced 
sufficient amounts of UDP-MurNAc-tetrapeptide 
precursors to sustain peptidoglycan cross-linking 
by Ldtfm leading to high-level resistance to 
ampicillin. However, sufficient amounts of 
UDP-MurNAc-pentapeptide remained for 
inhibition of transglycosylation by 
glycopeptides. Binding of the drugs to the 
pentapeptide stem of lipid intermediate II at the 
outer surface of the membrane is likely to 
account for inhibition of peptidoglycan 
polymerization since formation of this complex 
is expected to have two effects. First, the transfer 
of the disaccharide-pentapeptide subunit to 
growing glycan chains by the 
glycosyltransferases is blocked due to steric 
hindrance. Second, the lipid carrier is 
sequestered and cannot be recycled for 
incorporation of disaccharide-tetrapeptide units 
(Fig. 1). Similarly, production of D-Lac-ending 
precursors by the Tn1546-encoded VanH 
dehydrogenase and VanA ligase in sufficient 
amounts for peptidoglycan synthesis does not 
lead to glycopeptide resistance as complete 
elimination of pentapeptide stems prior to 
translocation of the precursors at the cell surface 
precursors is also required (26). This is mainly 
achieved by production of the VanX dipeptidase 
which cleaves the dipeptide D-Ala-D-Ala formed 
by the Ddl ligase and thereby limits synthesis of 
precursors ending in D-Ala5 (10). In addition, a 
D,D-carboxypeptidases (VanY) hydrolyzes D-
Ala5 of late peptidoglycan precursors to 
completely eliminate precursors containing the 
target of glycopeptides (10). The resulting 
tetrapeptide stems cannot be used as donors by 
the D,D-transpeptidases (PBPs) since the energy 
for cross-link formation originates from the D-
Ala4-D-Ala5 or D-Ala4-D-Lac5 bond (24). Thus, 
production of tetrapeptide by VanY releases 
inhibition of glycosyltransferases by 
glycopeptides although the resulting precursors 
cannot alone sustain peptidoglycan 
polymerization. In contrast, Ldtfm uses the 
energy of L-Lys3-D-Ala4 bond and the fifth 
residue of peptide stems is therefore fully 
dispensable with this mode of peptidoglycan 
cross-linking. 
The second selection scheme revealed that 
the selective pressure of glycopeptides alone can 
lead to cross-resistance to glycopeptides and β-
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lactam antibiotics (Fig. 2B). The L,D-
transpeptidation pathway was activated in the 
resulting mutant, G9, since its peptidoglycan 
contained mainly L-Lys3→D-iAsx-L-Lys3 cross-
links. Production of precursors containing the 
tetrapeptide stem essential for the cross-linking 
activity of Ldtfm was predominant in the 
cytoplasm of G9 (Fig. 3 and Table 1). An in 
vitro assay performed in the presence of 
ampicillin to inactivate the PBPs indicated that 
selection by glycopeptides led to activation of a 
cryptic D,D-carboxypeptidase which is not 
produced by the parental strain D344S (Table 1). 
This enzyme is therefore responsible for 
production of the tetrapeptide substrate of Ldtfm, 
as previously described for mutant M512 (18). 
Sequencing of the ldtfm gene and Western blot 
analysis using anti Ldtfm antibodies (data not 
shown) did not reveal any difference between the 
parental strain D344S and the mutants M512, 
M9, and G9. Thus, activation of the L,D-
transpeptidation pathway involved production of 
the tetrapeptide substrate of Ldtfm rather than a 
modification of this enzyme. Since substitution 
at the 4th and 5th positions of stem peptides was 
excluded by detailed analyses of mature 
peptidoglycan and its precursors, these data 
establish that L,D-transpeptidation is a novel 
mechanism of glycopeptide resistance.  
The structure of the dimers of mutant M9 
(Fig. 4) indicated that two types of donor stems 
(tetrapeptide and tetrapeptide-iAsn) and two 
types of acceptor stems (tripeptide-iAsn and 
tetrapeptide-iAsn) were used for cross-link 
formation in all four possible combinations. 
Ldtfm displays the same specificity in vitro (16). 
The enzyme is structurally unrelated to the 
PBPs, contains a catalytic Cys residue instead of 
Ser, and cross-links disaccharide-peptides in a β-
lactam-insensitive L,D-transpeptidation reaction 
(16, 27). Thus, the specificity of Ldtfm accounts 
both for the peptidoglycan structure of mutants 
M9 and G9 and the lack of inhibition of 
peptidoglycan cross-linking by ampicillin and 
glycopeptides since these drugs do not interact 
with the enzyme and its substrate, respectively. 
Considering the wide distribution of Ldtfm 
homologues in eubacteria, this mechanism of 
cross-resistance may potentially emerge in 
various pathogens. 
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FOOTNOTES 
 
1The abbreviations used are: BHI, brain heart infusion; MIC, minimum inhibitory concentration; MS, 
mass spectrometry; MS/MS, tandem mass spectrometry; PBP, penicillin-binding protein; rp-HPLC, 
reverse-phase high-pressure liquid chromatography. 
 
 
FIGURE LEGENDS 
 
Fig. 1. Peptidoglycan assembly in Enterococcus faecium. (A) In wild-type strains, β-lactams act as 
suicide substrates and inactivate the D,D-transpeptidase module of penicillin-binding proteins (PBPs). 
Glycopeptides bind to the peptidyl-D-Ala4-D-Ala5 extremity of peptidoglycan precursors and block 
transglycosylation by steric hindrance. Binding of the latter drugs to lipid intermediate II at the outer 
surface of the membrane (as represented) is thought to sequester the lipid carrier. Binding of 
glycopeptides to pentapeptide stems also inhibits the D,D-transpeptidase activity of the PBPs. (B) 
Activation of the L,D-transpeptidation pathway in mutants of E. faecium results from production of 
cytoplasmic precursors containing a tetrapeptide stem. The resulting precursors do not interact with 
glycopeptides and are cross-linked by the β-lactam-insensitive L,D-transpeptidase (Ldtfm). D-iAsx; D-iso-
aspartyl or D-iso-asparaginyl residue; D-iGln, D-iso-glutaminyl; D-iGlu, D-iso-glutamyl; GlcNAc, N-
acetylglucosamine; MurNAc, N-acetylmuramic acid; P, phosphate.. 
 
Fig. 2. MICs of vancomycin, teicoplanin, and ampicillin for derivatives of E. faecium D344S.  (A) 
Mutant M1, M2, M3, M4, and M512 were obtained by five consecutive selections steps on increasing 
concentration of ampicillin (18). Four additional selection steps with glycopeptides were required to 
obtain high-level cross-resistance to vancomycin, teicoplanin, and ampicillin. (B) Mutants G1 to G9 were 
obtained by serial selection with glycopeptides.  
H
AL author m
anuscript    inserm
-00185307, version 1
 9
 
Fig. 3. MS/MS analysis of peak at m/z 1,079.35 corresponding to UDP-MurNAc-tetrapeptide. 
Cytoplasmic nucleotide precursors of mutant M9 were purified, separated by rp-HPLC, and identified by 
mass spectrometry and tandem mass spectrometry. Fragmentation of the peak at m/z 1,079.35 gave ions at 
m/z 675.27 and 490.19 corresponding to the MurNAc-tetrapeptide and lactoyl-tetrapeptide moieties of the 
molecule. Peak at m/z 401.21 matched the predicted value for loss of the D-alanine residue at the C-
terminal position of lactoyl-tetrapeptide (m/z 490.19). Loss of additional L-Lys and D-Glu gave ion at m/z 
273.14 and 144.05, respectively. The peaks at m/z 347.19, 258.12, 218.14, and 129.09 matched the 
expected mass of D-iGlu-L-Lys-D-Ala, D-iGlu-L-Lys, L-Lys-D-Ala, and L-Lys, respectively. 
 
Fig. 4. Structure of the peptidoglycan of mutant M9. (A) rp-HPLC profile of lactoyl-peptides. 
Peptidoglycan was digested with muramidases and treated with ammonium hydroxide to cleave the ether 
link internal to MurNAc. This treatment also converts D-iso-asparaginyl into D-iso-aspartatyl (D-iAsp) 
residues. mAU, absorbance unit X 103 at 210 nm. (B) Schematic representation of dimers generated by 
L,D-transpeptidation. All multimers of M9 contained L-Lys3→D-iAsp-L-Lys3 cross-links. Variations 
occurred in the free side chain (presence or absence of D-iAsp) and at the 4th position of the acceptor stem 
peptide (presence of Gly, D-Ala or absence of a residue). The diversity of monomers resulted from 
variations at the same positions. (C) Peptidoglycan composition. The relative abundance (%) of the 
material in the peaks was calculated by integration of the absorbance at 210 nm. The structure of lactoyl-
peptides was deduced from the mass and confirmed by tandem mass spectrometry for all monomers and 
dimers. Mass, observed monoisotopic mass. 
 
Fig. 5. Sequencing of a dimer of M9 (peak 11) by tandem mass spectrometry. Fragmentation of the 
ion at m/z 1,118.5 (A) and inferred structure (B). Boxes indicate ions generated by cleavage at single 
peptide bounds. D-Lac, D-lactoyl.  
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Table 1. Characteristics of E. faecium D344S and derivatives selected on glycopeptide and β-lactam 
antibiotics. 
 
 MICs (µg/ml) a UDP-MurNAc-peptides (%) b D,D-carboxypeptidase activity 
(nmol/min/mg) c 
Strain Vm Te Ap  Tetra Penta Without Ap With Ap 
D344S 4 0.25 0.06 7 93 7.6 ± 3.1 < 1.0 
M512 8 0.5 >2,000 60 40 38.3 ± 15.5 32.1 ± 11.6
M9 1,000 1,000 >2,000 > 99 < 1 18.5 ± 3.6 17.5 ± 5.5 
G9 1,000 256 >2,000 92 8 50.7 ± 13.1 42.9 ± 10.7
 
a Vm, vancomycin ; Te, teicoplanin ; Ap, ampicillin. 
b Bacteria were grown to an optical density of 0.35 at 650 nm and treated with bacitracin 200 µg/ml for 5 
min to accumulate the precursors. After extraction with formic acid, nucleotide precursors were purified 
by rp-HPLC and identified by mass spectrometry. The relative abundance (%) of UDP-MurNAc-
tetrapeptide (Tetra) and UDP-MurNAc-pentapeptide (Penta) was calculated by integration of absorbance 
at 262 nm. 
c Hydrolysis of D-Ala from pentapeptide L-Ala-D-iGlu-L-Lys-D-Ala-D-Ala by D,D-carboxypeptidase 
activity in membrane fractions was determined using D-amino oxydase coupled to peroxidase in the 
presence (with Ap) or absence (without Ap) of ampicillin (20 µg/ml). 
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